Targeting the gastrointestinal tract to treat type 2 diabetes

Paige V. Bauer, Frank A. Duca

Research output: Contribution to journalReview article

12 Citations (Scopus)

Abstract

The rising global rates of type 2 diabetes and obesity present a significant economic and social burden, underscoring the importance for effective and safe therapeutic options. The success of glucagon-like-peptide-1 receptor agonists in the treatment of type 2 diabetes, along with the potent glucose-lowering effects of bariatric surgery, highlight the gastrointestinal tract as a potential target for diabetes treatment. Furthermore, recent evidence suggests that the gut plays a prominent role in the ability of metformin to lower glucose levels. As such, the current review highlights some of the current and potential pathways in the gut that could be targeted to improve glucose homeostasis, such as changes in nutrient sensing, gut peptides, gut microbiota and bile acids. A better understanding of these pathways will lay the groundwork for novel gut-targeted antidiabetic therapies, some of which have already shown initial promise.

Original languageEnglish (US)
Pages (from-to)R95-R113
JournalJournal of Endocrinology
Volume230
Issue number3
DOIs
StatePublished - Jan 1 2016
Externally publishedYes

Fingerprint

Type 2 Diabetes Mellitus
Gastrointestinal Tract
Glucose
Bariatric Surgery
Metformin
Therapeutics
Bile Acids and Salts
Hypoglycemic Agents
Homeostasis
Obesity
Economics
Food
Peptides

Keywords

  • Bile acids
  • Gut
  • Gut microbiota
  • Gut sensing
  • Metformin

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

Targeting the gastrointestinal tract to treat type 2 diabetes. / Bauer, Paige V.; Duca, Frank A.

In: Journal of Endocrinology, Vol. 230, No. 3, 01.01.2016, p. R95-R113.

Research output: Contribution to journalReview article

@article{03438b73bf81402ca163d18c536ee7aa,
title = "Targeting the gastrointestinal tract to treat type 2 diabetes",
abstract = "The rising global rates of type 2 diabetes and obesity present a significant economic and social burden, underscoring the importance for effective and safe therapeutic options. The success of glucagon-like-peptide-1 receptor agonists in the treatment of type 2 diabetes, along with the potent glucose-lowering effects of bariatric surgery, highlight the gastrointestinal tract as a potential target for diabetes treatment. Furthermore, recent evidence suggests that the gut plays a prominent role in the ability of metformin to lower glucose levels. As such, the current review highlights some of the current and potential pathways in the gut that could be targeted to improve glucose homeostasis, such as changes in nutrient sensing, gut peptides, gut microbiota and bile acids. A better understanding of these pathways will lay the groundwork for novel gut-targeted antidiabetic therapies, some of which have already shown initial promise.",
keywords = "Bile acids, Gut, Gut microbiota, Gut sensing, Metformin",
author = "Bauer, {Paige V.} and Duca, {Frank A.}",
year = "2016",
month = "1",
day = "1",
doi = "10.1530/JOE-16-0056",
language = "English (US)",
volume = "230",
pages = "R95--R113",
journal = "Journal of Endocrinology",
issn = "0022-0795",
publisher = "Society for Endocrinology",
number = "3",

}

TY - JOUR

T1 - Targeting the gastrointestinal tract to treat type 2 diabetes

AU - Bauer, Paige V.

AU - Duca, Frank A.

PY - 2016/1/1

Y1 - 2016/1/1

N2 - The rising global rates of type 2 diabetes and obesity present a significant economic and social burden, underscoring the importance for effective and safe therapeutic options. The success of glucagon-like-peptide-1 receptor agonists in the treatment of type 2 diabetes, along with the potent glucose-lowering effects of bariatric surgery, highlight the gastrointestinal tract as a potential target for diabetes treatment. Furthermore, recent evidence suggests that the gut plays a prominent role in the ability of metformin to lower glucose levels. As such, the current review highlights some of the current and potential pathways in the gut that could be targeted to improve glucose homeostasis, such as changes in nutrient sensing, gut peptides, gut microbiota and bile acids. A better understanding of these pathways will lay the groundwork for novel gut-targeted antidiabetic therapies, some of which have already shown initial promise.

AB - The rising global rates of type 2 diabetes and obesity present a significant economic and social burden, underscoring the importance for effective and safe therapeutic options. The success of glucagon-like-peptide-1 receptor agonists in the treatment of type 2 diabetes, along with the potent glucose-lowering effects of bariatric surgery, highlight the gastrointestinal tract as a potential target for diabetes treatment. Furthermore, recent evidence suggests that the gut plays a prominent role in the ability of metformin to lower glucose levels. As such, the current review highlights some of the current and potential pathways in the gut that could be targeted to improve glucose homeostasis, such as changes in nutrient sensing, gut peptides, gut microbiota and bile acids. A better understanding of these pathways will lay the groundwork for novel gut-targeted antidiabetic therapies, some of which have already shown initial promise.

KW - Bile acids

KW - Gut

KW - Gut microbiota

KW - Gut sensing

KW - Metformin

UR - http://www.scopus.com/inward/record.url?scp=84986246074&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84986246074&partnerID=8YFLogxK

U2 - 10.1530/JOE-16-0056

DO - 10.1530/JOE-16-0056

M3 - Review article

C2 - 27496374

AN - SCOPUS:84986246074

VL - 230

SP - R95-R113

JO - Journal of Endocrinology

JF - Journal of Endocrinology

SN - 0022-0795

IS - 3

ER -